Ocean Biomedical, Inc. (OCEA)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ocean Biomedical, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 9,087 |
| Nov 16, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 456 |
| Nov 13, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 38,757 |
| Nov 12, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 300,225 |
| Nov 11, 2026 | 0.0001 | 0.0001 | 0.0000 | 0.0000 | 564,823 |
| Nov 10, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 56,283 |
| Nov 9, 2026 | 0.0001 | 0.0004 | 0.0001 | 0.0001 | 54,033 |
| Nov 6, 2026 | 0.0001 | 0.0004 | 0.0001 | 0.0001 | 9,611 |
| Nov 5, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 1,000 |
| Nov 4, 2026 | 0.0001 | 0.0004 | 0.0001 | 0.0004 | 51,752 |
| Nov 3, 2026 | 0.0001 | 0.0005 | 0.0001 | 0.0005 | 1,739 |
| Nov 2, 2026 | 0.0002 | 0.0006 | 0.0002 | 0.0002 | 2,994 |
| Oct 30, 2026 | 0.0002 | 0.0006 | 0.0002 | 0.0003 | 22,181 |
| Oct 29, 2026 | 0.0002 | 0.0006 | 0.0001 | 0.0002 | 182,154 |
| Oct 27, 2026 | 0.0008 | 0.0008 | 0.0008 | 0.0008 | 166 |
| Oct 23, 2026 | 0.0005 | 0.0008 | 0.0005 | 0.0008 | 28,313 |
| Oct 20, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 110 |
| Oct 19, 2026 | 0.0000 | 0.0005 | 0.0000 | 0.0005 | 3,143 |
| Oct 16, 2026 | 0.0006 | 0.0006 | 0.0001 | 0.0006 | 312 |
| Oct 15, 2026 | 0.0002 | 0.0002 | 0.0002 | 0.0002 | 57,557 |
| Name | Shares | % | Source |
|---|---|---|---|
SkyView Investment Advisors, LLC | 40.0K | 0.0% | 13F |
FNY Investment Advisers, LLC | 600 | 0.0% | 13F |
Top institutional holders
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation.
The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients.
The company was incorporated in 2019 and is based in Providence, Rhode Island.
based on 232.37M shares outstanding
30d Avg
73.71K
60d Avg
60.86K
90d Avg
62.95K
Ocean Biomedical, Inc. (OTC: OCEA) traded at $0.0001 on Nov 17, 2026. 52-week range: $0.0000 to $0.0059. The company is in the Healthcare sector (Biotechnology).